Emerging antibodies for the treatment of multiple myeloma
作者： Flora Zagouri , Evangelos Terpos , Efstathios Kastritis , Meletios A. Dimopoulos
DOI: 10.1080/14728214.2016.1186644
关键词: Daratumumab 、 Milatuzumab 、 Siltuximab 、 Elotuzumab 、 Dacetuzumab 、 Pharmacology 、 Isatuximab 、 Lucatumumab 、 Medicine 、 Tositumomab 、 Internal medicine 、 Oncology
摘要: ABSTRACTIntroduction: Monoclonal antibodies mark the beginning of a new era in context multiple myeloma (MM) treatment. Numerous have been tested or are currently development for patients with MM, order to improve tolerability and quality life.Areas covered: This manuscript reviews emerging treatment MM i.e. elotuzumab, daratumumab, MOR03087, isatuximab, bevacizumab, cetuximab, siltuximab, tocilizumab, elsilimomab, azintrel, rituximab, tositumomab, milatuzumab, lucatumumab, dacetuzumab, figitumumab, dalotuzumab, AVE1642, tabalumab, pembrolizumab, pidilizumab, nivolumab.Expert opinion: Amongst these antibodies, elotuzumab which targets SLAMF-7 daratumumab CD38, recently approved by FDA relapsed/refractory MM. Both agents well tolerated. Multiple clinical trials incorporating monoclonal ongoing. Of special interest anticipated results phase III clinical...
sci-hub.se 参考文章(94)
Ayed O. Ayed, Lung-Ji Chang, Jan S. Moreb, Immunotherapy for multiple myeloma: Current status and future directions Critical Reviews in Oncology Hematology. ,vol. 96, pp. 399- 412 ,(2015) , 10.1016/J.CRITREVONC.2015.06.006
Robert Z. Orlowski, Liana Gercheva, Cathy Williams, Heather Sutherland, Tadeusz Robak, Tamás Masszi, Vesselina Goranova-Marinova, Meletios A. Dimopoulos, James D. Cavenagh, Ivan Špička, Angelo Maiolino, Alexander Suvorov, Joan Bladé, Olga Samoylova, Thomas A. Puchalski, Manjula Reddy, Rajesh Bandekar, Helgi van de Velde, Hong Xie, Jean-Franςois Rossi, A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma American Journal of Hematology. ,vol. 90, pp. 42- 49 ,(2015) , 10.1002/AJH.23868
Anke Kretz-Rommel, Fenghua Qin, Naveen Dakappagari, Roxanne Cofiell, Susan J. Faas, Katherine S. Bowdish, Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy Journal of Immunology. ,vol. 180, pp. 699- 705 ,(2008) , 10.4049/JIMMUNOL.180.2.699
Asher A. Chanan-Khan, Ivan Borrello, Kelvin P. Lee, Donna E. Reece, Development of target-specific treatments in multiple myeloma. British Journal of Haematology. ,vol. 151, pp. 3- 15 ,(2010) , 10.1111/J.1365-2141.2010.08262.X
George J. Weiner, Building better monoclonal antibody-based therapeutics Nature Reviews Cancer. ,vol. 15, pp. 361- 370 ,(2015) , 10.1038/NRC3930
Flora Zagouri, Evangelos Terpos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos, An update on the use of lenalidomide for the treatment of multiple myeloma Expert Opinion on Pharmacotherapy. ,vol. 16, pp. 1865- 1877 ,(2015) , 10.1517/14656566.2015.1067681
S Z Usmani, R Sexton, S Ailawadhi, J J Shah, J Valent, M Rosenzweig, B Lipe, J A Zonder, S Fredette, B Durie, A Hoering, B Bartlett, R Z Orlowski, Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer Journal. ,vol. 5, ,(2015) , 10.1038/BCJ.2015.62
Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C. Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Imran Khan, Clarissa M. Uhlar, Jianping Wang, A. Kate Sasser, Nedjad Losic, Steen Lisby, Linda Basse, Nikolai Brun, Paul G. Richardson, Targeting CD38 with daratumumab monotherapy in multiple myeloma The New England Journal of Medicine. ,vol. 373, pp. 1207- 1219 ,(2015) , 10.1056/NEJMOA1506348
H Jiang, C Acharya, G An, M Zhong, X Feng, L Wang, N Dasilva, Z Song, G Yang, F Adrian, L Qiu, P Richardson, N C Munshi, Y-T Tai, K C Anderson, SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. ,vol. 30, pp. 399- 408 ,(2016) , 10.1038/LEU.2015.240
M S van der Veer, M de Weers, B van Kessel, J M Bakker, S Wittebol, P W H I Parren, H M Lokhorst, T Mutis, The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies Blood Cancer Journal. ,vol. 1, ,(2011) , 10.1038/BCJ.2011.42